1. Home
  2. Public Health
  3. Pharmaceutical Services
  4. Etravirine (Intelence®)
Print this page Reduce font size Increase font size

Etravirine (Intelence®)

Highly Specialised Drugs Program Declaration Form*

nsw health logo

 Patient's Name:

  ____________________________________
 Medical Record Number:   ____________________________________
 Medicare Number:     ____________________________________
                

I certify that the above patient meets the Pharmaceutical Benefits Advisory Committee's criteria for funding under Section 100 of the National Health Act, 1953.



Criteria

Treatment in combination with other antiretroviral agents, of HIV infection in an antiretroviral experienced patient with:

a. evidence of HIV replication (viral load greater than 10,000 copies per mL); and/or

b. CD4 cell counts of less than 500 per cubic millimetre.

A patient must have failed previous treatment with, or have resistance to, 3 different antiretroviral regimens which have included:

i.   at least 1 non-nucleoside reverse transcriptase inhibitor; and

ii.  at least 1 nucleoside reverse transcriptase inhibitor; and

iii. at least 1 protease inhibitor

 

Specialist /Authorised Prescriber

 Signature:  ____________________________________
 Name:  ____________________________________
 Date:  ____________________________________

*To be completed by the specialist or authorised prescriber initiating drug treatment, and retained by the hospital Pharmacy Department.

July 2009

Print this page Reduce font size Increase font size

This web page is managed and authorised by Pharmaceutical Services of Centre for Health Protection of the NSW Department of Health. Last updated: 3 July, 2009